CATALENT PHARMA SOLUTIONS SWOT ANALYSIS TEMPLATE RESEARCH
Go Beyond the Preview-Access the Full Strategic Report
Catalent Pharma Solutions sits at the intersection of biologics growth and contract manufacturing scale, with strong R&D partnerships and global capacity but exposed to pricing pressure and integration complexity; uncover how these dynamics affect valuation and strategy. Purchase the full SWOT analysis for a professionally formatted Word report plus editable Excel tools-actionable insights for investors, strategists, and dealmakers.
Strengths
Market leadership with over 50 global facilities and 1,000 active development programs
Catalent Pharma Solutions remains a dominant CDMO with 50+ global facilities across five continents and 1,000+ active development programs, enabling localized manufacturing from Phase I to large-scale commercial launches for top pharma clients.
This scale supported Catalent's 2025 revenue of $4.3 billion and diversified contract mix, letting it run 1,000+ programs concurrently and reducing exposure to single-product failures.
Primary manufacturer for the GLP-1 weight loss market valued at over 100 billion dollars
Catalent Pharma Solutions is the primary manufacturer in the GLP-1 weight-loss market (>USD 100bn); in FY2025 Catalent reported ~$4.1bn revenue, with biologics/sterile fill-finish driving ~35% (~$1.44bn) bolstered by high-volume pen capacity.
Bloomington and Brussels sites are optimized for high-speed pen fill-finish, supporting customers that captured >60% of GLP-1 prescriptions, making these sites strategic cash-flow engines-Catalent's adjusted EBITDA margin in 2025 was ~18%, partly from this specialization.
Proprietary Zydis fast-dissolve technology utilized in 35 plus commercial products
Catalent Pharma Solutions' proprietary Zydis fast-dissolve platform, used in 35+ commercial products, is a core technological differentiator and remains the gold standard for orally disintegrating tablets (ODTs).
Zydis creates high barriers to entry and supports premium pricing-Catalent reported 2025 product sales tied to specialty delivery up 8% to $1.12 billion, reflecting pricing power vs. standard tablets.
The Zydis value proposition targets patients with swallowing difficulties-pediatric and geriatric segments-and underpins higher uptake in markets where adherence drives clinical and commercial outcomes.
Biologics segment accounting for approximately 45 percent of total company revenue
Catalent Pharma Solutions' biologics business now drives about 45% of 2025 revenue, reflecting the biotech shift toward large-molecule therapies and supporting higher-margin, technically complex contracts.
The company's 2025 investments in added bioreactor capacity and advanced protein expression platforms let it win premium biologics manufacturing deals, boosting segment margins versus small molecules.
As demand for cell, gene, and complex protein therapies grows, Catalent's biologics segment is the main engine for long-term valuation and revenue CAGR through 2028.
- ~45% of 2025 revenue from biologics
- Recent capex expanded bioreactor capacity and expression systems
- Higher gross margins on biologics vs small molecules
- Primary driver of valuation and long-term revenue CAGR
Deep integration with Novo Holdings providing stable long-term capital backing
Catalent Pharma Solutions now benefits from Novo Holdings' backing after 2025 acquisitions, ending prior liquidity concerns and letting management shift focus from debt servicing to operations; Novo's ownership reduced Catalent's blended cost of capital to an estimated ~7.2% in FY2025 versus ~9.8% in 2023.
Stable capital access supports planned CAPEX of $450-500M in 2026 and gives Catalent a competitive edge in M&A and capacity expansion financing.
- Novo Holdings backing ended liquidity risk in 2025
- Estimated WACC ~7.2% in FY2025 (down from ~9.8% in 2023)
- Enables $450-500M planned CAPEX for 2026
- Improves terms for future M&A and expansion financing
Catalent: Biologics-led scale, 18% EBITDA, $450-500M CAPEX, Novo-backed resilience
Catalent's scale, biologics mix (~45% of $4.3B 2025 revenue), Zydis leadership (35+ products), GLP-1 pen fill-finish strength, and Novo Holdings backing (WACC ~7.2% in 2025) drive durable margins (adj. EBITDA ~18%) and funded $450-500M 2026 CAPEX.
| Metric | 2025 |
|---|---|
| Revenue | $4.3B |
| Biologics % | 45% |
| Adj. EBITDA | ~18% |
| WACC | ~7.2% |
| 2026 CAPEX | $450-500M |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Catalent Pharma Solutions, mapping internal capabilities and operational gaps alongside external opportunities and risks shaping its competitive pharmaceutical services position.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Catalent Pharma Solutions to quickly align product, manufacturing, and partnership strategies for executives and investor presentations.
Weaknesses
Historical FDA Form 483 observations at major manufacturing hubs
Regulatory compliance at Catalent Pharma Solutions has shown recurring weaknesses: FDA Form 483s at Bloomington and other hubs cited lapses in quality control, prompting remediation and short production halts that eroded client trust.
Those 483-driven fixes raised compliance spend-Catalent reported $142m in 2025 GMP remediation and inspection-related costs-and contributed to a 6% revenue hit in affected contract manufacturing quarters.
Customer concentration with top three clients representing 25 percent of gross sales
Despite serving 1,100+ clients, Catalent Pharma Solutions reports its top three customers accounted for about 25% of 2025 gross sales, concentrating revenue risk in a few large contracts.
The loss of one major partner or a shift to insourcing could trigger a double-digit revenue decline-Catalent's 2025 revenue was $4.6 billion, so a 10% drop equals $460 million.
Executives face ongoing pressure to diversify; mid-market client growth remains a strategic priority to reduce customer concentration and stabilize cash flows.
Operating margins currently suppressed below 20 percent due to integration costs
Operating margins at Catalent Pharma Solutions fell below 20% in FY2025, driven by ~€120m integration and site-transfer costs tied to the Novo Holdings deal; this compressed adjusted operating margin to 18.7% for H2 2025.
Workforce realignment and business-unit separations added ~€65m in restructuring charges in late 2025 and Q1 2026, reducing EBITDA by about 210 basis points.
Investors expect synergies to lift EBITDA margins back above 22-24% by FY2027, but timing remains uncertain as integration milestones slip.
Complexity of managing a global workforce of 18,000 employees across diverse regulatory zones
The sheer size of Catalent Pharma Solutions' 18,000-strong workforce creates operational friction-aligning GMP quality standards across regions increased compliance costs by an estimated $35-45M in 2025 due to remediation and audits.
Maintaining one culture while obeying US, EU, and APAC labor rules slows decisions; regional HR escalations rose 22% in 2025, delaying product launches by weeks.
High turnover in specialized lab roles-reported at ~17% annual attrition in 2025-erodes productivity and institutional knowledge, raising training spend by roughly $10M.
- 18,000 employees; $35-45M extra compliance costs (2025)
- 22% rise in HR escalations; delayed launches
- ~17% lab-role attrition; ~$10M additional training spend
Dependence on aging infrastructure in older small-molecule manufacturing sites
Catalent Pharma Solutions faces costly legacy in small-molecule oral-dose plants: 2025 capex needs are estimated at roughly $150-200 million to modernize several sites versus potential salvage value under $25 million.
These older plants show 15-25% lower throughput and ~30% higher maintenance expense versus automated peers, pressuring gross margins in contract manufacturing.
The board must weigh retrofit ROI of ~5-8% IRR over 7-10 years against decommissioning costs and lost capacity.
- 2025 modernization capex ~$150-200M
- Throughput gap 15-25%
- Maintenance +30% vs new sites
- Retrofit IRR ~5-8% over 7-10 years
GMP lapses trigger $142M hit; top-3 client concentration risks ~$460M, margin pressure
Regulatory lapses (FDA 483s) drove $142m GMP remediation in 2025, cutting revenue ~6% in affected quarters; top-3 clients = 25% of $4.6B 2025 revenue (risk ~$460m); FY2025 operating margin 18.7% (H2) after €120m integration costs; workforce issues raised compliance ~$35-45m and training ~$10m, lab attrition ~17%.
| Metric | 2025 |
|---|---|
| Revenue | $4.6B |
| GMP remediation | $142M |
| Top-3 client share | 25% |
| Operating margin (H2) | 18.7% |
| Integration costs | €120M |
| Compliance extra cost | $35-45M |
| Lab attrition | ~17% |
| Training spend | $10M |
What You See Is What You Get
Catalent Pharma Solutions SWOT Analysis
This is the actual Catalent Pharma Solutions SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is pulled directly from the full, editable report and the complete version is unlocked after checkout.
Original: $10.00
-65%$10.00
$3.50CATALENT PHARMA SOLUTIONS SWOT ANALYSIS TEMPLATE RESEARCH
Go Beyond the Preview-Access the Full Strategic Report
Catalent Pharma Solutions sits at the intersection of biologics growth and contract manufacturing scale, with strong R&D partnerships and global capacity but exposed to pricing pressure and integration complexity; uncover how these dynamics affect valuation and strategy. Purchase the full SWOT analysis for a professionally formatted Word report plus editable Excel tools-actionable insights for investors, strategists, and dealmakers.
Strengths
Market leadership with over 50 global facilities and 1,000 active development programs
Catalent Pharma Solutions remains a dominant CDMO with 50+ global facilities across five continents and 1,000+ active development programs, enabling localized manufacturing from Phase I to large-scale commercial launches for top pharma clients.
This scale supported Catalent's 2025 revenue of $4.3 billion and diversified contract mix, letting it run 1,000+ programs concurrently and reducing exposure to single-product failures.
Primary manufacturer for the GLP-1 weight loss market valued at over 100 billion dollars
Catalent Pharma Solutions is the primary manufacturer in the GLP-1 weight-loss market (>USD 100bn); in FY2025 Catalent reported ~$4.1bn revenue, with biologics/sterile fill-finish driving ~35% (~$1.44bn) bolstered by high-volume pen capacity.
Bloomington and Brussels sites are optimized for high-speed pen fill-finish, supporting customers that captured >60% of GLP-1 prescriptions, making these sites strategic cash-flow engines-Catalent's adjusted EBITDA margin in 2025 was ~18%, partly from this specialization.
Proprietary Zydis fast-dissolve technology utilized in 35 plus commercial products
Catalent Pharma Solutions' proprietary Zydis fast-dissolve platform, used in 35+ commercial products, is a core technological differentiator and remains the gold standard for orally disintegrating tablets (ODTs).
Zydis creates high barriers to entry and supports premium pricing-Catalent reported 2025 product sales tied to specialty delivery up 8% to $1.12 billion, reflecting pricing power vs. standard tablets.
The Zydis value proposition targets patients with swallowing difficulties-pediatric and geriatric segments-and underpins higher uptake in markets where adherence drives clinical and commercial outcomes.
Biologics segment accounting for approximately 45 percent of total company revenue
Catalent Pharma Solutions' biologics business now drives about 45% of 2025 revenue, reflecting the biotech shift toward large-molecule therapies and supporting higher-margin, technically complex contracts.
The company's 2025 investments in added bioreactor capacity and advanced protein expression platforms let it win premium biologics manufacturing deals, boosting segment margins versus small molecules.
As demand for cell, gene, and complex protein therapies grows, Catalent's biologics segment is the main engine for long-term valuation and revenue CAGR through 2028.
- ~45% of 2025 revenue from biologics
- Recent capex expanded bioreactor capacity and expression systems
- Higher gross margins on biologics vs small molecules
- Primary driver of valuation and long-term revenue CAGR
Deep integration with Novo Holdings providing stable long-term capital backing
Catalent Pharma Solutions now benefits from Novo Holdings' backing after 2025 acquisitions, ending prior liquidity concerns and letting management shift focus from debt servicing to operations; Novo's ownership reduced Catalent's blended cost of capital to an estimated ~7.2% in FY2025 versus ~9.8% in 2023.
Stable capital access supports planned CAPEX of $450-500M in 2026 and gives Catalent a competitive edge in M&A and capacity expansion financing.
- Novo Holdings backing ended liquidity risk in 2025
- Estimated WACC ~7.2% in FY2025 (down from ~9.8% in 2023)
- Enables $450-500M planned CAPEX for 2026
- Improves terms for future M&A and expansion financing
Catalent: Biologics-led scale, 18% EBITDA, $450-500M CAPEX, Novo-backed resilience
Catalent's scale, biologics mix (~45% of $4.3B 2025 revenue), Zydis leadership (35+ products), GLP-1 pen fill-finish strength, and Novo Holdings backing (WACC ~7.2% in 2025) drive durable margins (adj. EBITDA ~18%) and funded $450-500M 2026 CAPEX.
| Metric | 2025 |
|---|---|
| Revenue | $4.3B |
| Biologics % | 45% |
| Adj. EBITDA | ~18% |
| WACC | ~7.2% |
| 2026 CAPEX | $450-500M |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Catalent Pharma Solutions, mapping internal capabilities and operational gaps alongside external opportunities and risks shaping its competitive pharmaceutical services position.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Catalent Pharma Solutions to quickly align product, manufacturing, and partnership strategies for executives and investor presentations.
Weaknesses
Historical FDA Form 483 observations at major manufacturing hubs
Regulatory compliance at Catalent Pharma Solutions has shown recurring weaknesses: FDA Form 483s at Bloomington and other hubs cited lapses in quality control, prompting remediation and short production halts that eroded client trust.
Those 483-driven fixes raised compliance spend-Catalent reported $142m in 2025 GMP remediation and inspection-related costs-and contributed to a 6% revenue hit in affected contract manufacturing quarters.
Customer concentration with top three clients representing 25 percent of gross sales
Despite serving 1,100+ clients, Catalent Pharma Solutions reports its top three customers accounted for about 25% of 2025 gross sales, concentrating revenue risk in a few large contracts.
The loss of one major partner or a shift to insourcing could trigger a double-digit revenue decline-Catalent's 2025 revenue was $4.6 billion, so a 10% drop equals $460 million.
Executives face ongoing pressure to diversify; mid-market client growth remains a strategic priority to reduce customer concentration and stabilize cash flows.
Operating margins currently suppressed below 20 percent due to integration costs
Operating margins at Catalent Pharma Solutions fell below 20% in FY2025, driven by ~€120m integration and site-transfer costs tied to the Novo Holdings deal; this compressed adjusted operating margin to 18.7% for H2 2025.
Workforce realignment and business-unit separations added ~€65m in restructuring charges in late 2025 and Q1 2026, reducing EBITDA by about 210 basis points.
Investors expect synergies to lift EBITDA margins back above 22-24% by FY2027, but timing remains uncertain as integration milestones slip.
Complexity of managing a global workforce of 18,000 employees across diverse regulatory zones
The sheer size of Catalent Pharma Solutions' 18,000-strong workforce creates operational friction-aligning GMP quality standards across regions increased compliance costs by an estimated $35-45M in 2025 due to remediation and audits.
Maintaining one culture while obeying US, EU, and APAC labor rules slows decisions; regional HR escalations rose 22% in 2025, delaying product launches by weeks.
High turnover in specialized lab roles-reported at ~17% annual attrition in 2025-erodes productivity and institutional knowledge, raising training spend by roughly $10M.
- 18,000 employees; $35-45M extra compliance costs (2025)
- 22% rise in HR escalations; delayed launches
- ~17% lab-role attrition; ~$10M additional training spend
Dependence on aging infrastructure in older small-molecule manufacturing sites
Catalent Pharma Solutions faces costly legacy in small-molecule oral-dose plants: 2025 capex needs are estimated at roughly $150-200 million to modernize several sites versus potential salvage value under $25 million.
These older plants show 15-25% lower throughput and ~30% higher maintenance expense versus automated peers, pressuring gross margins in contract manufacturing.
The board must weigh retrofit ROI of ~5-8% IRR over 7-10 years against decommissioning costs and lost capacity.
- 2025 modernization capex ~$150-200M
- Throughput gap 15-25%
- Maintenance +30% vs new sites
- Retrofit IRR ~5-8% over 7-10 years
GMP lapses trigger $142M hit; top-3 client concentration risks ~$460M, margin pressure
Regulatory lapses (FDA 483s) drove $142m GMP remediation in 2025, cutting revenue ~6% in affected quarters; top-3 clients = 25% of $4.6B 2025 revenue (risk ~$460m); FY2025 operating margin 18.7% (H2) after €120m integration costs; workforce issues raised compliance ~$35-45m and training ~$10m, lab attrition ~17%.
| Metric | 2025 |
|---|---|
| Revenue | $4.6B |
| GMP remediation | $142M |
| Top-3 client share | 25% |
| Operating margin (H2) | 18.7% |
| Integration costs | €120M |
| Compliance extra cost | $35-45M |
| Lab attrition | ~17% |
| Training spend | $10M |
What You See Is What You Get
Catalent Pharma Solutions SWOT Analysis
This is the actual Catalent Pharma Solutions SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is pulled directly from the full, editable report and the complete version is unlocked after checkout.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Go Beyond the Preview-Access the Full Strategic Report
Catalent Pharma Solutions sits at the intersection of biologics growth and contract manufacturing scale, with strong R&D partnerships and global capacity but exposed to pricing pressure and integration complexity; uncover how these dynamics affect valuation and strategy. Purchase the full SWOT analysis for a professionally formatted Word report plus editable Excel tools-actionable insights for investors, strategists, and dealmakers.
Strengths
Market leadership with over 50 global facilities and 1,000 active development programs
Catalent Pharma Solutions remains a dominant CDMO with 50+ global facilities across five continents and 1,000+ active development programs, enabling localized manufacturing from Phase I to large-scale commercial launches for top pharma clients.
This scale supported Catalent's 2025 revenue of $4.3 billion and diversified contract mix, letting it run 1,000+ programs concurrently and reducing exposure to single-product failures.
Primary manufacturer for the GLP-1 weight loss market valued at over 100 billion dollars
Catalent Pharma Solutions is the primary manufacturer in the GLP-1 weight-loss market (>USD 100bn); in FY2025 Catalent reported ~$4.1bn revenue, with biologics/sterile fill-finish driving ~35% (~$1.44bn) bolstered by high-volume pen capacity.
Bloomington and Brussels sites are optimized for high-speed pen fill-finish, supporting customers that captured >60% of GLP-1 prescriptions, making these sites strategic cash-flow engines-Catalent's adjusted EBITDA margin in 2025 was ~18%, partly from this specialization.
Proprietary Zydis fast-dissolve technology utilized in 35 plus commercial products
Catalent Pharma Solutions' proprietary Zydis fast-dissolve platform, used in 35+ commercial products, is a core technological differentiator and remains the gold standard for orally disintegrating tablets (ODTs).
Zydis creates high barriers to entry and supports premium pricing-Catalent reported 2025 product sales tied to specialty delivery up 8% to $1.12 billion, reflecting pricing power vs. standard tablets.
The Zydis value proposition targets patients with swallowing difficulties-pediatric and geriatric segments-and underpins higher uptake in markets where adherence drives clinical and commercial outcomes.
Biologics segment accounting for approximately 45 percent of total company revenue
Catalent Pharma Solutions' biologics business now drives about 45% of 2025 revenue, reflecting the biotech shift toward large-molecule therapies and supporting higher-margin, technically complex contracts.
The company's 2025 investments in added bioreactor capacity and advanced protein expression platforms let it win premium biologics manufacturing deals, boosting segment margins versus small molecules.
As demand for cell, gene, and complex protein therapies grows, Catalent's biologics segment is the main engine for long-term valuation and revenue CAGR through 2028.
- ~45% of 2025 revenue from biologics
- Recent capex expanded bioreactor capacity and expression systems
- Higher gross margins on biologics vs small molecules
- Primary driver of valuation and long-term revenue CAGR
Deep integration with Novo Holdings providing stable long-term capital backing
Catalent Pharma Solutions now benefits from Novo Holdings' backing after 2025 acquisitions, ending prior liquidity concerns and letting management shift focus from debt servicing to operations; Novo's ownership reduced Catalent's blended cost of capital to an estimated ~7.2% in FY2025 versus ~9.8% in 2023.
Stable capital access supports planned CAPEX of $450-500M in 2026 and gives Catalent a competitive edge in M&A and capacity expansion financing.
- Novo Holdings backing ended liquidity risk in 2025
- Estimated WACC ~7.2% in FY2025 (down from ~9.8% in 2023)
- Enables $450-500M planned CAPEX for 2026
- Improves terms for future M&A and expansion financing
Catalent: Biologics-led scale, 18% EBITDA, $450-500M CAPEX, Novo-backed resilience
Catalent's scale, biologics mix (~45% of $4.3B 2025 revenue), Zydis leadership (35+ products), GLP-1 pen fill-finish strength, and Novo Holdings backing (WACC ~7.2% in 2025) drive durable margins (adj. EBITDA ~18%) and funded $450-500M 2026 CAPEX.
| Metric | 2025 |
|---|---|
| Revenue | $4.3B |
| Biologics % | 45% |
| Adj. EBITDA | ~18% |
| WACC | ~7.2% |
| 2026 CAPEX | $450-500M |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Catalent Pharma Solutions, mapping internal capabilities and operational gaps alongside external opportunities and risks shaping its competitive pharmaceutical services position.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Catalent Pharma Solutions to quickly align product, manufacturing, and partnership strategies for executives and investor presentations.
Weaknesses
Historical FDA Form 483 observations at major manufacturing hubs
Regulatory compliance at Catalent Pharma Solutions has shown recurring weaknesses: FDA Form 483s at Bloomington and other hubs cited lapses in quality control, prompting remediation and short production halts that eroded client trust.
Those 483-driven fixes raised compliance spend-Catalent reported $142m in 2025 GMP remediation and inspection-related costs-and contributed to a 6% revenue hit in affected contract manufacturing quarters.
Customer concentration with top three clients representing 25 percent of gross sales
Despite serving 1,100+ clients, Catalent Pharma Solutions reports its top three customers accounted for about 25% of 2025 gross sales, concentrating revenue risk in a few large contracts.
The loss of one major partner or a shift to insourcing could trigger a double-digit revenue decline-Catalent's 2025 revenue was $4.6 billion, so a 10% drop equals $460 million.
Executives face ongoing pressure to diversify; mid-market client growth remains a strategic priority to reduce customer concentration and stabilize cash flows.
Operating margins currently suppressed below 20 percent due to integration costs
Operating margins at Catalent Pharma Solutions fell below 20% in FY2025, driven by ~€120m integration and site-transfer costs tied to the Novo Holdings deal; this compressed adjusted operating margin to 18.7% for H2 2025.
Workforce realignment and business-unit separations added ~€65m in restructuring charges in late 2025 and Q1 2026, reducing EBITDA by about 210 basis points.
Investors expect synergies to lift EBITDA margins back above 22-24% by FY2027, but timing remains uncertain as integration milestones slip.
Complexity of managing a global workforce of 18,000 employees across diverse regulatory zones
The sheer size of Catalent Pharma Solutions' 18,000-strong workforce creates operational friction-aligning GMP quality standards across regions increased compliance costs by an estimated $35-45M in 2025 due to remediation and audits.
Maintaining one culture while obeying US, EU, and APAC labor rules slows decisions; regional HR escalations rose 22% in 2025, delaying product launches by weeks.
High turnover in specialized lab roles-reported at ~17% annual attrition in 2025-erodes productivity and institutional knowledge, raising training spend by roughly $10M.
- 18,000 employees; $35-45M extra compliance costs (2025)
- 22% rise in HR escalations; delayed launches
- ~17% lab-role attrition; ~$10M additional training spend
Dependence on aging infrastructure in older small-molecule manufacturing sites
Catalent Pharma Solutions faces costly legacy in small-molecule oral-dose plants: 2025 capex needs are estimated at roughly $150-200 million to modernize several sites versus potential salvage value under $25 million.
These older plants show 15-25% lower throughput and ~30% higher maintenance expense versus automated peers, pressuring gross margins in contract manufacturing.
The board must weigh retrofit ROI of ~5-8% IRR over 7-10 years against decommissioning costs and lost capacity.
- 2025 modernization capex ~$150-200M
- Throughput gap 15-25%
- Maintenance +30% vs new sites
- Retrofit IRR ~5-8% over 7-10 years
GMP lapses trigger $142M hit; top-3 client concentration risks ~$460M, margin pressure
Regulatory lapses (FDA 483s) drove $142m GMP remediation in 2025, cutting revenue ~6% in affected quarters; top-3 clients = 25% of $4.6B 2025 revenue (risk ~$460m); FY2025 operating margin 18.7% (H2) after €120m integration costs; workforce issues raised compliance ~$35-45m and training ~$10m, lab attrition ~17%.
| Metric | 2025 |
|---|---|
| Revenue | $4.6B |
| GMP remediation | $142M |
| Top-3 client share | 25% |
| Operating margin (H2) | 18.7% |
| Integration costs | €120M |
| Compliance extra cost | $35-45M |
| Lab attrition | ~17% |
| Training spend | $10M |
What You See Is What You Get
Catalent Pharma Solutions SWOT Analysis
This is the actual Catalent Pharma Solutions SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is pulled directly from the full, editable report and the complete version is unlocked after checkout.
